Strongbridge Biopharma Stock Price, News & Analysis (NASDAQ:SBBP)

$6.75 +0.10 (+1.50 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$6.65
Today's Range$6.55 - $6.90
52-Week Range$2.75 - $9.02
Volume212,453 shs
Average Volume322,047 shs
Market Capitalization$273.08 million
P/E Ratio-2.00
Dividend YieldN/A
Beta1.98

About Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma logoStrongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Debt-to-Equity Ratio-1.89%
Current Ratio4.70%
Quick Ratio4.61%

Price-To-Earnings

Trailing P/E Ratio-1.99999411766436
Forward P/E Ratio-2.36
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.58 per share
Price / Book1.89

Profitability

Trailing EPS($3.40)
Net Income$-48,590,000.00
Net MarginsN/A
Return on Equity-181.90%
Return on Assets-38.62%

Miscellaneous

Employees24
Outstanding Shares40,160,000

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings data on Tuesday, May, 16th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.16. View Strongbridge Biopharma's Earnings History.

When will Strongbridge Biopharma make its next earnings announcement?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Strongbridge Biopharma.

Where is Strongbridge Biopharma's stock going? Where will Strongbridge Biopharma's stock price be in 2018?

3 Wall Street analysts have issued 12-month price objectives for Strongbridge Biopharma's shares. Their forecasts range from $12.00 to $18.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $14.67 in the next twelve months. View Analyst Ratings for Strongbridge Biopharma.

What are Wall Street analysts saying about Strongbridge Biopharma stock?

Here are some recent quotes from research analysts about Strongbridge Biopharma stock:

  • 1. According to Zacks Investment Research, "Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. " (1/17/2018)
  • 2. Cantor Fitzgerald analysts commented, "Acquisition of U.S. and Canadian rights to MACRILEN, marks early start to commercialize in rare endocrine disorders." (1/17/2018)

Who are some of Strongbridge Biopharma's key competitors?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:

  • John H. Johnson, Chairman of the Board (Age 58)
  • Matthew Pauls J.D., Chief Executive Officer, Director (Age 46)
  • A. Brian Davis, Chief Financial Officer (Age 48)
  • Stephen J. Long, Chief Legal Officer (Age 50)
  • Robert Lutz, Chief Business Officer (Age 46)
  • Ruth Thieroff-Ekerdt M.D., Chief Medical Officer (Age 59)
  • Richard S. Kollender, Director
  • Garheng Kong M.D. Ph.D., Director (Age 41)
  • Marten Steen, Director (Age 39)
  • Hilde H. Steineger, Director (Age 52)

Who owns Strongbridge Biopharma stock?

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (7.93%), Armistice Capital LLC (7.15%), Vivo Capital LLC (6.11%), BlackRock Inc. (3.57%), Lyon Street Capital LLC (3.50%) and Opaleye Management Inc. (3.11%). View Institutional Ownership Trends for Strongbridge Biopharma.

Who sold Strongbridge Biopharma stock? Who is selling Strongbridge Biopharma stock?

Strongbridge Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC and Millennium Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

Who bought Strongbridge Biopharma stock? Who is buying Strongbridge Biopharma stock?

Strongbridge Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Lyon Street Capital LLC, BlackRock Inc., Stonepine Capital Management LLC, Broadfin Capital LLC, Perceptive Advisors LLC, Hudson Bay Capital Management LP and 683 Capital Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy Strongbridge Biopharma stock?

Shares of Strongbridge Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of Strongbridge Biopharma stock can currently be purchased for approximately $6.75.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $273.08 million. The biotechnology company earns $-48,590,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Strongbridge Biopharma employs 24 workers across the globe.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (SBBP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Strongbridge Biopharma (NASDAQ:SBBP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.67$14.67$13.33$13.33
Price Target Upside: 86.84% upside86.84% upside131.88% upside102.02% upside

Strongbridge Biopharma (NASDAQ:SBBP) Consensus Price Target History

Price Target History for Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma (NASDAQ:SBBP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018HC WainwrightReiterated RatingBuy$18.00LowView Rating Details
1/17/2018Cantor FitzgeraldSet Price TargetBuy$14.00LowView Rating Details
8/10/2017OppenheimerInitiated CoverageOutperform$12.00HighView Rating Details
12/28/2016JMP SecuritiesReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Strongbridge Biopharma (NASDAQ:SBBP) Earnings History and Estimates Chart

Earnings by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma (NASDAQ SBBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018        
11/14/2017Q3 2017($0.46)($0.39)$1.77 million$2.53 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.34)($0.34)$0.84 million$1.53 millionViewListenView Earnings Details
5/16/20173/31/2017($0.49)($0.33)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.32)($0.25)ViewN/AView Earnings Details
12/23/2016Q2 2016($0.36)ViewN/AView Earnings Details
5/17/2016Q1($0.63)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Strongbridge Biopharma (NASDAQ:SBBP) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.86 EPS
Next Year EPS Consensus Estimate: $-1.22 EPS

Dividends

Dividend History for Strongbridge Biopharma (NASDAQ:SBBP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Strongbridge Biopharma (NASDAQ SBBP)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Strongbridge Biopharma (NASDAQ SBBP) News Headlines

Source:
DateHeadline
Strongbridge Biopharma (SBBP) and BioMarin Pharmaceutical (BMRN) Critical ContrastStrongbridge Biopharma (SBBP) and BioMarin Pharmaceutical (BMRN) Critical Contrast
www.americanbankingnews.com - February 20 at 2:48 PM
Strongbridge Biopharma plc (SBBP) Receives Average Rating of "Hold" from BrokeragesStrongbridge Biopharma plc (SBBP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 18 at 1:30 AM
Head to Head Contrast: Strongbridge Biopharma (SBBP) and Cesca Therapeutics (KOOL)Head to Head Contrast: Strongbridge Biopharma (SBBP) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - February 9 at 5:34 PM
Zacks: Brokerages Anticipate Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 MillionZacks: Brokerages Anticipate Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 Million
www.americanbankingnews.com - February 9 at 2:50 AM
Strongbridge Biopharma plc (SBBP) Expected to Announce Earnings of -$0.31 Per ShareStrongbridge Biopharma plc (SBBP) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Strongbridge completes $33.8M stock saleStrongbridge completes $33.8M stock sale
finance.yahoo.com - February 2 at 3:26 PM
BidaskClub Downgrades Strongbridge Biopharma (SBBP) to HoldBidaskClub Downgrades Strongbridge Biopharma (SBBP) to Hold
www.americanbankingnews.com - February 2 at 6:52 AM
Strongbridge Biopharma (SBBP) Prices 5M Offering of Ordinary Shares at $6.75/ShareStrongbridge Biopharma (SBBP) Prices 5M Offering of Ordinary Shares at $6.75/Share
www.streetinsider.com - January 28 at 6:35 AM
BidaskClub Downgrades Strongbridge Biopharma (SBBP) to BuyBidaskClub Downgrades Strongbridge Biopharma (SBBP) to Buy
www.americanbankingnews.com - January 27 at 12:52 AM
Strongbridge Biopharma (SBBP) Plans Offering of 5M Ordinary SharesStrongbridge Biopharma (SBBP) Plans Offering of 5M Ordinary Shares
www.streetinsider.com - January 24 at 9:52 AM
Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary SharesStrongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares
finance.yahoo.com - January 24 at 9:52 AM
Strongbridge Biopharma plc (SBBP) Given Average Rating of "Buy" by AnalystsStrongbridge Biopharma plc (SBBP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Zacks: Brokerages Expect Strongbridge Biopharma plc (SBBP) to Announce -$0.31 EPSZacks: Brokerages Expect Strongbridge Biopharma plc (SBBP) to Announce -$0.31 EPS
www.americanbankingnews.com - January 21 at 1:08 PM
Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s SyndromeStrongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
finance.yahoo.com - January 18 at 7:17 PM
Strongbridge Biopharma (SBBP) Rating Reiterated by HC WainwrightStrongbridge Biopharma (SBBP) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - January 18 at 7:00 PM
Strongbridge Biopharma (SBBP) Cut to Hold at Zacks Investment ResearchStrongbridge Biopharma (SBBP) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 17 at 9:50 PM
Cantor Fitzgerald Analysts Give Strongbridge Biopharma (SBBP) a $14.00 Price TargetCantor Fitzgerald Analysts Give Strongbridge Biopharma (SBBP) a $14.00 Price Target
www.americanbankingnews.com - January 17 at 11:52 AM
Aeterna Zentaris Enters into Licensing and Assignment Agreement with Strongbridge for Macrilen™ (macimorelin) in the U.S. and CanadaAeterna Zentaris Enters into Licensing and Assignment Agreement with Strongbridge for Macrilen™ (macimorelin) in the U.S. and Canada
www.nasdaq.com - January 17 at 11:09 AM
AEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s WhyAEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s Why
finance.yahoo.com - January 17 at 11:09 AM
Strongbridge Biopharma plc (SBBP) Sees Large Increase in Short InterestStrongbridge Biopharma plc (SBBP) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 14 at 2:32 AM
Strongbridge Biopharma plc (SBBP) Expected to Post Quarterly Sales of $2.98 MillionStrongbridge Biopharma plc (SBBP) Expected to Post Quarterly Sales of $2.98 Million
www.americanbankingnews.com - January 6 at 3:54 AM
Strongbridge Biopharma plc (SBBP) Sees Large Drop in Short InterestStrongbridge Biopharma plc (SBBP) Sees Large Drop in Short Interest
www.americanbankingnews.com - January 1 at 3:07 AM
Strongbridge Biopharma plc (SBBP) Receives Average Rating of "Buy" from AnalystsStrongbridge Biopharma plc (SBBP) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 30 at 1:50 AM
Strongbridge Biopharma (SBBP) Raised to Buy at BidaskClubStrongbridge Biopharma (SBBP) Raised to Buy at BidaskClub
www.americanbankingnews.com - December 27 at 9:53 AM
Head to Head Contrast: Alimera Sciences (ALIM) & Strongbridge Biopharma (SBBP)Head to Head Contrast: Alimera Sciences (ALIM) & Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - December 26 at 9:24 AM
Onconova Therapeutics (ONTX) vs. Strongbridge Biopharma (SBBP) Financial ReviewOnconova Therapeutics (ONTX) vs. Strongbridge Biopharma (SBBP) Financial Review
www.americanbankingnews.com - December 24 at 9:33 PM
Strongbridge shares rise after report highlights price hikes on $109,500-a-year drugStrongbridge shares rise after report highlights price hikes on $109,500-a-year drug
finance.yahoo.com - December 18 at 11:47 AM
Strongbridge Biopharma plc Announces New Employment Inducement AwardsStrongbridge Biopharma plc Announces New Employment Inducement Awards
finance.yahoo.com - December 14 at 11:25 AM
Strongbridge Biopharma plc (SBBP) to Post FY2017 Earnings of ($2.84) Per Share, Cantor Fitzgerald ForecastsStrongbridge Biopharma plc (SBBP) to Post FY2017 Earnings of ($2.84) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - December 11 at 1:24 AM
Strongbridge Biopharma (SBBP) Stock Rating Reaffirmed by Cantor FitzgeraldStrongbridge Biopharma (SBBP) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - December 9 at 9:22 AM
Contrasting Cardiome Pharma (CRME) & Strongbridge Biopharma (SBBP)Contrasting Cardiome Pharma (CRME) & Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - December 8 at 11:22 AM
2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma
finance.yahoo.com - December 6 at 3:46 PM
Strongbridge Biopharma plc (SBBP) Given Consensus Rating of "Buy" by BrokeragesStrongbridge Biopharma plc (SBBP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 5 at 5:46 PM
Strongbridge Biopharma (SBBP) Receives New Coverage from Analysts at Cantor FitzgeraldStrongbridge Biopharma (SBBP) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - December 5 at 4:32 PM
Zacks: Analysts Expect Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 MillionZacks: Analysts Expect Strongbridge Biopharma plc (SBBP) Will Announce Quarterly Sales of $2.98 Million
www.americanbankingnews.com - December 3 at 9:00 AM
Strongbridge Biopharma PLC (SBBP) Cut to "Hold" at Zacks Investment ResearchStrongbridge Biopharma PLC (SBBP) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 22 at 7:18 PM
Strongbridge Biopharma PLC (SBBP) Rating Reiterated by HC WainwrightStrongbridge Biopharma PLC (SBBP) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 19 at 6:20 PM
Edited Transcript of SBBP earnings conference call or presentation 14-Nov-17 1:30pm GMTEdited Transcript of SBBP earnings conference call or presentation 14-Nov-17 1:30pm GMT
finance.yahoo.com - November 18 at 11:35 AM
Analyzing Strongbridge Biopharma PLC (SBBP) & Kadmon Holdings (KDMN)Analyzing Strongbridge Biopharma PLC (SBBP) & Kadmon Holdings (KDMN)
www.americanbankingnews.com - November 17 at 7:22 AM
Strongbridge Biopharma plc to Host Earnings CallStrongbridge Biopharma plc to Host Earnings Call
finance.yahoo.com - November 14 at 7:36 AM
Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsStrongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 7:36 AM
Strongbridge Biopharma PLC (SBBP) Expected to Announce Quarterly Sales of $1.77 MillionStrongbridge Biopharma PLC (SBBP) Expected to Announce Quarterly Sales of $1.77 Million
www.americanbankingnews.com - November 14 at 6:24 AM
Strongbridge Biopharma PLC (SBBP) Expected to Post Earnings of -$0.42 Per ShareStrongbridge Biopharma PLC (SBBP) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - November 12 at 1:24 PM
Strongbridge Biopharma PLC (SBBP) Set to Announce Earnings on TuesdayStrongbridge Biopharma PLC (SBBP) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - November 7 at 10:08 AM
Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on NovemberStrongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November
www.nasdaq.com - November 7 at 9:53 AM
Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017
finance.yahoo.com - November 7 at 9:53 AM
Strongbridge Biopharma plc to Present at the Stifel 2017 Healthcare ConferenceStrongbridge Biopharma plc to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 9:53 AM
What You Must Know About Strongbridge Biopharma plc’s (SBBP) Financial StrengthWhat You Must Know About Strongbridge Biopharma plc’s (SBBP) Financial Strength
finance.yahoo.com - November 1 at 8:29 AM
Zacks: Brokerages Expect Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.77 MillionZacks: Brokerages Expect Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.77 Million
www.americanbankingnews.com - October 25 at 6:20 PM
Strongbridge Biopharma PLC (SBBP) Rating Increased to Hold at Zacks Investment ResearchStrongbridge Biopharma PLC (SBBP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - October 15 at 8:26 PM

SEC Filings

Strongbridge Biopharma (NASDAQ:SBBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Strongbridge Biopharma (NASDAQ:SBBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Strongbridge Biopharma (NASDAQ SBBP) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.